Adimmune’s new COVID-19 vaccine clinical trials confirms vaccine effectiveness

Adimmune Biotech Corporation(4142) announced today, Adimmune’s independently researched COVID-19 vaccine, has undergone vaccine antibody neutralization at the National Taiwan University’s School of Medicine, Department of Medical Examination and Biotechnology, Professor Zhang Shuyuan's Laboratory. Mice serum injected with COVID-19 have shown neutralizing antibodies with high potency, confirming the effectiveness of Adimmune’s COVID-19 vaccine on rats, marking a new milestone towards human clinical testing for a Tawainese COVID-19 vaccine.

This is a important milestone towards Adimmune’s COVID-19 vaccine development, Adimmine will continue to work with the Taiwanese National Health Research Institute in conducting a challenge test to confirm the safety of the COVID-19 vaccine’s safety, and will discuss with regulatory agencies as the vaccine enters human clinical trial phase.